The case for assessing the full value of new tuberculosis vaccines-Reference-Cited by-同舟云学术

The case for assessing the full value of new tuberculosis vaccines

Published:2020-03 Issue:3 Volume:55 Page:1902414
ISSN:0903-1936
Container-title:European Respiratory Journal
language:en
Short-container-title:Eur Respir J

Author:

Gebreselassie Nebiat,Hutubessy Raymond,Vekemans Johan^ORCID,den Boon Saskia,Kasaeva Tereza,Zignol Matteo

Publisher

European Respiratory Society (ERS)

Subject

Pulmonary and Respiratory Medicine

Reference18 articles.

1. World Health Organization. Global Tuberculosis Report . Geneva, World Health Organization, 2019.

2. Epidemiology: A mortal foe

3. What have we learnt about BCG vaccination in the last 20 years?;Dockrell;Front Immunol,2017

4. Bacille Calmette-Guerin vaccination: the current situation in Europe

5. World Health Organization. End TB Strategy: Global Strategy and Targets for Tuberculosis Prevention, Care and Control after 2015 . Geneva, World Health Organization, 2014.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making;BMC Medicine;2023-07-04

2. Chemistry and pharmacological diversity of benzothiazepine—Excellent pathway to drug discovery;Journal of Molecular Structure;2023-05

3. Advances in development of new tuberculosis vaccines;Current Opinion in Pulmonary Medicine;2023-03-02

4. Bacillus Calmette–Guérin–induced interleukin‐10 inhibits S100A8/A9 production and hinders development of T helper type 1 memory in mice;European Journal of Immunology;2023-02-16

5. The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study;PLOS Medicine;2023-01-24